PATENT CLAIM ANALYSIS

Application Number: 16172570
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "254050"]

Abstract:
Disclosed are pharmaceutical compositions comprising mdivi-1 and nutlin-3, individually and in combination, for topical or intravitreal ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma, optic neuropathies including Leber Hereditary Optic Neuropathy, arteritic or non-arteritic Ischemic Optic Neuropathy, and retinal artery and vein occlusions.

Claim (Index 2):
The method of  claim 1 , wherein the composition is administered to said person once to four times per day.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 97.0
- Lexical Diversity: 1.30233
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12715384', '14991744', '15812605', '13876465', '15455670']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7289204826667528
- 35 USC 102 Novelty (BERT): 0.4471086030888623
- Combined Prediction Score: 0.7007392947089638
- Mean Citation Score: 119.648908
- Max Citation Score: 185.72223
- Similarity Product: 184.20727994260133

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test